A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Of AJ201 In Patients

Spinal and Bulbar Muscular Atrophy Clinical Trial

Official title:
A Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, First-In-Patient Study Of AJ201 To Evaluate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics In Adults With Spinal And Bulbar Muscular Atrophy (SBMA)

Status Active, not recruiting

Clinical Trial Summary

This is a phase 1/2a randomized, double-blind study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of study drug AJ201 in subjects with Spinal and Bulbar Muscular Atrophy (SBMA).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05517603
Study type	Interventional
Source	AnnJi Pharmaceutical Co., Ltd.
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	February 28, 2023
Completion date	April 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04944940` - Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)
Recruiting	`NCT03555578` - Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"
Completed	`NCT00303446` - Dutasteride to Treat Spinal and Bulbar Muscular Atrophy (SBMA)	Phase 2
Recruiting	`NCT06411912` - A Study of NIDO-361 in Patients With SBMA	Phase 2
Completed	`NCT02156141` - High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy	N/A
Completed	`NCT02024932` - Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy	Phase 2
Recruiting	`NCT06169046` - A Placebo-controlled Study of Clenbuterol in Spinal and Bulbar Muscular Atrophy	Phase 2